These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
267 related articles for article (PubMed ID: 29296182)
1. MicroRNA-410-3p attenuates gemcitabine resistance in pancreatic ductal adenocarcinoma by inhibiting HMGB1-mediated autophagy. Xiong J; Wang D; Wei A; Ke N; Wang Y; Tang J; He S; Hu W; Liu X Oncotarget; 2017 Dec; 8(64):107500-107512. PubMed ID: 29296182 [TBL] [Abstract][Full Text] [Related]
2. Gemcitabine enhances OSI-027 cytotoxicity by upregulation of miR-663a in pancreatic ductal adenocarcinoma cells. Huang B; Wang J; Chen Q; Qu C; Zhang J; Chen E; Zhang Y; Wang Y; Ni L; Liang T Am J Transl Res; 2019; 11(1):473-485. PubMed ID: 30788003 [TBL] [Abstract][Full Text] [Related]
3. MicroRNA-323-3p inhibits cell invasion and metastasis in pancreatic ductal adenocarcinoma via direct suppression of SMAD2 and SMAD3. Wang C; Liu P; Wu H; Cui P; Li Y; Liu Y; Liu Z; Gou S Oncotarget; 2016 Mar; 7(12):14912-24. PubMed ID: 26908446 [TBL] [Abstract][Full Text] [Related]
4. Elevated miR-483-3p expression is an early event and indicates poor prognosis in pancreatic ductal adenocarcinoma. Wang C; Sun Y; Wu H; Yu S; Zhang L; Meng Y; Liu M; Yang H; Liu P; Mao X; Lu Z; Chen J Tumour Biol; 2015 Dec; 36(12):9447-56. PubMed ID: 26124009 [TBL] [Abstract][Full Text] [Related]
5. MicroRNA-301a-3p promotes pancreatic cancer progression via negative regulation of SMAD4. Xia X; Zhang K; Cen G; Jiang T; Cao J; Huang K; Huang C; Zhao Q; Qiu Z Oncotarget; 2015 Aug; 6(25):21046-63. PubMed ID: 26019136 [TBL] [Abstract][Full Text] [Related]
6. Involvement of anti-tumor Idichi T; Seki N; Kurahara H; Fukuhisa H; Toda H; Shimonosono M; Yamada Y; Arai T; Kita Y; Kijima Y; Mataki Y; Maemura K; Natsugoe S Oncotarget; 2018 Jun; 9(48):28849-28865. PubMed ID: 29988949 [TBL] [Abstract][Full Text] [Related]
7. Down-regulation of miR-30a-5p is Associated with Poor Prognosis and Promotes Chemoresistance of Gemcitabine in Pancreatic Ductal Adenocarcinoma. Zhou L; Jia S; Ding G; Zhang M; Yu W; Wu Z; Cao L J Cancer; 2019; 10(21):5031-5040. PubMed ID: 31602254 [TBL] [Abstract][Full Text] [Related]
8. Hypoxia-induced epigenetic regulation of miR-485-3p promotes stemness and chemoresistance in pancreatic ductal adenocarcinoma via SLC7A11-mediated ferroptosis. Liu X; Huang Z; Chen Q; Chen K; Liu W; Liu G; Chu X; Li D; Ma Y; Tian X; Yang Y Cell Death Discov; 2024 May; 10(1):262. PubMed ID: 38811540 [TBL] [Abstract][Full Text] [Related]
9. The microRNA expression signature of pancreatic ductal adenocarcinoma by RNA sequencing: anti-tumour functions of the Yonemori K; Seki N; Idichi T; Kurahara H; Osako Y; Koshizuka K; Arai T; Okato A; Kita Y; Arigami T; Mataki Y; Kijima Y; Maemura K; Natsugoe S Oncotarget; 2017 Sep; 8(41):70097-70115. PubMed ID: 29050264 [TBL] [Abstract][Full Text] [Related]
10. Antagonistic Roles of the Tumor Suppressor miR-210-3p and Oncomucin MUC4 Forming a Negative Feedback Loop in Pancreatic Adenocarcinoma. Boukrout N; Souidi M; Lahdaoui F; Duchêne B; Neve B; Coppin L; Leteurtre E; Torrisani J; Van Seuningen I; Jonckheere N Cancers (Basel); 2021 Dec; 13(24):. PubMed ID: 34944818 [TBL] [Abstract][Full Text] [Related]
11. Functional Significance and Therapeutic Potential of miR-15a Mimic in Pancreatic Ductal Adenocarcinoma. Guo S; Fesler A; Huang W; Wang Y; Yang J; Wang X; Zheng Y; Hwang GR; Wang H; Ju J Mol Ther Nucleic Acids; 2020 Mar; 19():228-239. PubMed ID: 31846800 [TBL] [Abstract][Full Text] [Related]
12. miR-186 and 326 predict the prognosis of pancreatic ductal adenocarcinoma and affect the proliferation and migration of cancer cells. Zhang ZL; Bai ZH; Wang XB; Bai L; Miao F; Pei HH PLoS One; 2015; 10(3):e0118814. PubMed ID: 25742499 [TBL] [Abstract][Full Text] [Related]
13. Downregulation of miR-301a-3p sensitizes pancreatic cancer cells to gemcitabine treatment via PTEN. Xia X; Zhang K; Luo G; Cen G; Cao J; Huang K; Qiu Z Am J Transl Res; 2017; 9(4):1886-1895. PubMed ID: 28469793 [TBL] [Abstract][Full Text] [Related]
14. The prognostic relevance of primary tumor location in patients undergoing resection for pancreatic ductal adenocarcinoma. Ling Q; Xu X; Ye P; Xie H; Gao F; Hu Q; Liu Z; Wei X; Röder C; Trauzold A; Kalthoff H; Zheng S Oncotarget; 2017 Feb; 8(9):15159-15167. PubMed ID: 28122349 [TBL] [Abstract][Full Text] [Related]
15. Nanoparticle-Mediated Therapy with miR-198 Sensitizes Pancreatic Cancer to Gemcitabine Treatment through Downregulation of VCP-Mediated Autophagy. Marin-Muller C; Li D; Lü JM; Liang Z; Vega-Martínez O; Crawford SE; Estes MK; Fisher WE; Chen C; Yao Q Pharmaceutics; 2023 Jul; 15(8):. PubMed ID: 37631252 [TBL] [Abstract][Full Text] [Related]
16. Upregulated MicroRNA-483-3p is an Early Event in Pancreatic Ductal Adenocarcinoma (PDAC) and as a Powerful Liquid Biopsy Biomarker in PDAC. Shao H; Zhang Y; Yan J; Ban X; Fan X; Chang X; Lu Z; Wu Y; Zong L; Mo S; Yu S; Chen J Onco Targets Ther; 2021; 14():2163-2175. PubMed ID: 33790579 [TBL] [Abstract][Full Text] [Related]
17. miR-409-3p sensitizes colon cancer cells to oxaliplatin by inhibiting Beclin-1-mediated autophagy. Tan S; Shi H; Ba M; Lin S; Tang H; Zeng X; Zhang X Int J Mol Med; 2016 Apr; 37(4):1030-8. PubMed ID: 26935807 [TBL] [Abstract][Full Text] [Related]
18. MiR-24-3p Inhibits the Progression of Pancreatic Ductal Adenocarcinoma Through LAMB3 Downregulation. Huang W; Gu J; Tao T; Zhang J; Wang H; Fan Y Front Oncol; 2019; 9():1499. PubMed ID: 32039003 [TBL] [Abstract][Full Text] [Related]